RESEARCH TRIANGLE PARK, NC--(Marketwire - October 1, 2008) - According to the recently
released report, "Pharmaceutical Alliance Management," pharmaceutical
companies that proactively monitor alliance health suffer 19% fewer failed
deals than companies that choose not to. Published by Cutting Edge
Information as a follow-on to the recent business development report,
"Business Development: Accelerating the Deal," this new study focuses on
the best practices that partner-of-choice pharmaceutical companies employ,
as well as resource benchmarks.
According to the study, one method for ensuring the ongoing health of an
alliance is the alliance health survey. Taking the time to regularly
assess the status of the licensing relationship promotes well-being within
the partnership and negates the potential for unforeseen deal killers. Any
potential issues stemming from cultural differences, miscommunications or
corporate restructuring will be uncovered before they become problems.
"In a faltering global economy, no pharmaceutical company wants to
hamstring profitable collaborations for anything less than truly critical
reasons," says Eric Bolesh, lead author of the report. "Taking a few hours
every month to analyze the partnership's status provides an ROI that few
functions within the company can match."
The insights within "Pharmaceutical Alliance Management" prevent these deal
destroyers, giving guidelines for effective partner communication and
internal coordination to ensure continuous alliance satisfaction. More
than 50 companies contributed to the study, which contains 150+ metrics,
including the following:
-- Resource support for alliance management groups
-- Prevalence of dedicated alliance management functions, by company size
-- Levels of historical deal satisfaction
-- Underlying reasons for unsuccessful deals
-- Key deal challenges
-- Inbound deals: functions involved in post-deal day-to-day activities
-- Outbound deals: functions involved in post-deal day-to-day activities
-- Use of alliance health surveys
-- Tools of the alliance health department
-- Surveyed companies' communication models
-- Steps to partner-of-choice status
For a complete licensing picture, Cutting Edge Information also offers
"Pharmaceutical Alliance Management," bundled with "Business Development:
Accelerating the Deal." Together these reports provide guidance and
benchmarking figures from the beginning stages of licensing -- deal
identification and due diligence -- through complicated deal negotiations
and the ever difficult task of alliance management.
For more information on the new alliance management study, as well as the
recent business report, please visit
www.PharmaDealMaking.com.
Contact Information: CONTACT INFORMATION:
Eric Bolesh
919-433-0209